EMERYVILLE, Calif. (AP) _ Adamas Pharmaceuticals Inc. (ADMS) on Thursday reported a loss of $33.2 million in its third quarter.
The Emeryville, California-based company said it had a loss of $1.22 per share.
The results beat Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.34 per share.
The drugmaker posted revenue of $10.6 million in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $10.1 million.
Adamas shares have decreased 50 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $16.97, a fall of 36 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ADMS at https://www.zacks.com/ap/ADMS